Why Aren’t More Medical Technologies Designed for Children?

Key Takeaways

• Only 0.5% FDA orthopaedic devices target children
• Just 2% AI radiology devices approved for pediatrics
• UK research allocates 5% budget to paediatrics
• Funding for children’s services fell 22% (2010‑2022)
• Survey seeks industry insight on paediatric tech barriers

Pulse Analysis

The disparity between adult and child health technology is more than a clinical oversight; it reflects a systemic market failure. Children constitute about 20% of the UK population, yet investment in paediatric devices lags dramatically behind adult counterparts. This gap not only hampers clinical outcomes for young patients but also signals untapped revenue potential for innovators willing to navigate the niche. Understanding the scale of the problem is the first step toward rebalancing research priorities and encouraging private‑sector participation.

Regulatory complexity, limited trial populations, and uncertain reimbursement pathways are often cited as deterrents for companies. Pediatric devices must meet stricter safety standards, and the smaller patient pool reduces the statistical power of studies, inflating development costs. Additionally, the fragmented nature of funding—where only a fraction of national research budgets targets paediatrics—creates a financing vacuum that discourages long‑term investment. These operational hurdles combine to produce a risk‑averse environment, prompting many firms to focus exclusively on adult markets.

Strategic interventions can turn barriers into opportunities. Targeted grant programs, tax incentives, and streamlined approval processes would lower entry costs for developers. Collaborative consortia that pool clinical data across hospitals can mitigate sample‑size challenges, while public‑private partnerships can share risk and accelerate time‑to‑market. By aligning policy incentives with market demand, the health‑tech ecosystem can foster innovations that improve outcomes for children and unlock a new growth segment for manufacturers. The upcoming NIHR‑Innovate UK survey aims to map these obstacles precisely, paving the way for evidence‑based reforms.